Dymista ® — Net Sales
Viatris Dymista ® — Net Sales decreased by 3.4% to $37.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 12.9%, from $42.80M to $37.30M. Over 4 years (FY 2021 to FY 2025), Dymista ® — Net Sales shows relatively stable performance with a -0.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market adoption and effective commercial execution for the product, while a decrease may signal rising competition, patent expirations, or shifts in prescribing patterns.
Detailed definition
This metric represents the total revenue generated from the sale of the Dymista product line, a specialized nasal spray...
Peer comparison
Comparable to branded specialty pharmaceutical product revenue lines at other global drug manufacturers, often evaluated against similar respiratory or allergy franchise performance.
vtrs_segment_dymista_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $54.60M | $35.00M | $38.10M | $44.00M | $55.50M | $38.60M | $41.80M | $53.20M | $57.70M | $44.10M | $45.00M | $48.20M | $55.00M | $43.50M | $41.30M | $42.80M | $48.40M | $33.80M | $38.60M | $37.30M |
| QoQ Change | — | -35.9% | +8.9% | +15.5% | +26.1% | -30.5% | +8.3% | +27.3% | +8.5% | -23.6% | +2.0% | +7.1% | +14.1% | -20.9% | -5.1% | +3.6% | +13.1% | -30.2% | +14.2% | -3.4% |
| YoY Change | — | — | — | — | +1.6% | +10.3% | +9.7% | +20.9% | +4.0% | +14.2% | +7.7% | -9.4% | -4.7% | -1.4% | -8.2% | -11.2% | -12.0% | -22.3% | -6.5% | -12.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's dymista ® — net sales?
- Viatris (VTRS) reported dymista ® — net sales of $37.30M in Q1 2026.
- How has Viatris's dymista ® — net sales changed year-over-year?
- Viatris's dymista ® — net sales decreased by 12.9% year-over-year, from $42.80M to $37.30M.
- What is the long-term trend for Viatris's dymista ® — net sales?
- Over 4 years (2021 to 2025), Viatris's dymista ® — net sales has grown at a -0.7% compound annual growth rate (CAGR), from $168.00M to $163.60M.
- What does dymista ® — net sales mean?
- The total revenue earned from sales of the Dymista nasal spray product.